Invention Grant
- Patent Title: IRE-1α inhibitors
-
Application No.: US14594400Application Date: 2015-01-12
-
Publication No.: US09693992B2Publication Date: 2017-07-04
- Inventor: Qingping Zeng , Andras Toro , John Bruce Patterson , Warren Stanfield Wade , Zoltan Zubovics , Yun Yang , Zhipeng Wu
- Applicant: MannKind Corporation
- Applicant Address: US CA Valencia
- Assignee: MannKind Corporation
- Current Assignee: MannKind Corporation
- Current Assignee Address: US CA Valencia
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; Benjamin D. Heuberger
- Main IPC: C07D311/16
- IPC: C07D311/16 ; C07D405/10 ; C07D417/04 ; A61K31/366 ; A61K31/343 ; A61K31/352 ; A61K31/37 ; A61K31/381 ; A61K31/4025 ; A61K31/404 ; A61K31/4045 ; A61K31/415 ; A61K31/4155 ; A61K31/4172 ; A61K31/4184 ; A61K31/423 ; A61K31/427 ; A61K31/4433 ; A61K31/4439 ; A61K31/452 ; A61K31/453 ; A61K31/454 ; A61K31/4545 ; A61K31/496 ; A61K31/5377 ; A61K45/06 ; C07D311/20 ; C07D311/94 ; C07D401/04 ; C07D405/04 ; C07D409/04 ; C07D217/02 ; C07D217/08 ; C07D311/12 ; C07D311/22 ; C07D401/12
Abstract:
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
Public/Granted literature
- US20150141424A1 IRE-1alpha INHIBITORS Public/Granted day:2015-05-21
Information query
